New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
11:20 EDTEXEL, RHHBYExelixis seen as potential target for Roche, TheStreet says
David Miller thinks Roche (RHHBY) will likely acquire Exelixis (EXEL) after the partners announced a phase III study of coBRIM in melanoma met its primary endpoint, reported TheStreet's Adam Feuerstein. Shares of Exelixis are up nearly 8% following this morning report on the trial. Reference Link
News For EXEL;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
09:23 EDTEXELExelixis files automatic mixed securities shelf
08:46 EDTEXEL, RHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 29, 2015
05:51 EDTEXELStocks with implied volatility movement; XOMA EXEL
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use